What is Geneseeq?
Geneseeq Technology Inc. stands as a prominent player in the Precision Oncology landscape, specializing in advanced Next-Generation Sequencing (NGS)-based solutions. Their offerings are designed to enhance cancer diagnosis, prognosis, treatment guidance, and drug development. By providing comprehensive genomic insights across a spectrum of cancer types, including solid tumors and hematologic malignancies, Geneseeq empowers oncologists, researchers, and patients. The company's portfolio encompasses central lab testing, local testing solutions, and bespoke research services, all geared towards accelerating the adoption of precision cancer care. Geneseeq's commitment to quality and efficiency is evident in its collaborations with biopharmaceutical and research partners, facilitating high-caliber genomic data generation and supporting translational research efforts.
How much funding has Geneseeq raised?
Geneseeq has raised a total of $127.9M across 3 funding rounds:
Series A
$4.8M
Series B
$9.1M
Series D
$114M
Series A (2014): $4.8M with participation from Beijing Beilu Pharmaceutical
Series B (2016): $9.1M led by Eastern Investment, Beijing Beilu Pharmaceutical, and Beijing D.Z Capital
Series D (2019): $114M supported by China Reform Holdings Corporation, Lilly Asia Ventures, and SoftBank China Venture Capital
Key Investors in Geneseeq
Lilly Asia Ventures
Lilly Asia Ventures is a leading biomedical venture capital firm with a focus on building companies that develop breakthrough products to treat diseases and improve human health.
Eastern Investment
Eastern Investment Corp operates within the Investment Banking sector, providing financial services and solutions.
Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co. Ltd is a company operating in the Pharmaceuticals industry, contributing to the healthcare sector.
What's next for Geneseeq?
With a substantial enterprise-level funding history, Geneseeq is strategically positioned for continued innovation and market penetration in the precision oncology space. The recent major strategic investment indicates a strong confidence from backers in the company's long-term vision and its capacity to scale its advanced NGS-based solutions. This capital infusion is expected to fuel further research and development, potentially expanding their diagnostic capabilities, enhancing their service offerings, and broadening their global reach. Geneseeq's focus on actionable genomic insights suggests a trajectory towards becoming an indispensable partner for biopharma companies and healthcare providers seeking to advance personalized cancer therapies.
See full Geneseeq company page
